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admission.
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Introduction
Beta-blockers have been established as important agents 
that reduce mortality and re-infarction in acute myocardial 
infarction (AMI) patients with left ventricular dysfunction 
[1–3]. In particular, the guidelines for management of ST-
segment elevation myocardial infarction (STEMI) from the 
American Heart Association/American College of Cardiol-
ogy and the European Society of Cardiology recommend the 
use of beta-blockers in AMI patients with heart failure or left 
ventricular dysfunction [4, 5]. However, these recommen-
dations are based on the results of studies conducted in the 
fibrinolytic era [6]. Recently, primary percutaneous coronary 
intervention (PCI), which has been reported to be associated 
with a lower mortality rate than fibrinolysis [7], has become 
a mainstream treatment for AMI. Primary PCI also plays an 
important role in reducing the incidence of left ventricular 
dysfunction following AMI in many patients. Patients with 
Killip class 1 on admission have been reported to have better 
prognosis than patients with higher Killip classes [8].
The clinical benefit of beta-blocker therapy after pri-
mary PCI in patients without pump failure has not been 
well established. Clarifying the efficacy of beta-blocker 
therapy in reducing mortality might provide a novel thera-
peutic strategy for AMI patients who undergo primary PCI. 
Therefore, in the present study we investigated the clinical 
benefit of beta-blocker therapy after primary PCI for Killip 
class 1 AMI patients.
Abstract The use of beta-blockers therapy has been rec-
ommended to reduce mortality in patients with left ventric-
ular dysfunction after acute myocardial infarction (AMI). 
Primary percutaneous coronary intervention (PCI), which 
has become the mainstay of treatment for AMI, is associ-
ated with a lower mortality than fibrinolysis. The benefits 
of beta-blockers after primary PCI in AMI patients without 
pump failure are unclear. We hypothesized that oral beta-
blocker therapy after primary PCI might reduce the mortal-
ity in AMI patients without pump failure. The assessment 
of lipophilic vs. hydrophilic statin therapy in acute myocar-
dial infarction (ALPS-AMI) study was a multi-center study 
that enrolled 508 AMI patients to compare the efficacy of 
hydrophilic and lipophilic statins in secondary prevention 
after myocardial infarction. We prospectively tracked car-
diovascular events for 3 years in 444 ALPS-AMI patients 
(median age 66 years; 18.2 % women) who had Killip class 
1 on admission and were discharged alive. The primary 
endpoint was all-cause mortality. The 3-year follow-up was 
completed in 413 patients (93.0 %). During this follow-up, 
21 patients (4.7 %) died. In Kaplan–Meier analysis, patients 
on beta-blockers had a significantly lower incidence of all-
cause mortality (2.7 vs. 7.3 %, log-rank p = 0.025). After 
adjusting for the calculated propensity score for using beta-
blockers, their use remained an independent predictor of 
all-cause mortality (hazard ratio 0.309; 95 % confidence 
interval 0.116–0.824; p = 0.019). In the statin era, the use 
of beta-blocker therapy after primary PCI is associated 
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This study was a retrospective sub-analysis of the assess-
ment of lipophilic vs. hydrophilic statin therapy in acute 
myocardial infarction (ALPS-AMI) study, which included 
508 patients enrolled between July 2008 and June 2010. 
The results of the ALPS-AMI study were described in 
detail in a recent publication [9]. In brief, the ALPS-AMI 
study [University Hospital Medical Information Net-
work Clinical Trials Registry of Japan registration number 
(UMIN-ID) 000001521] was a prospective multi-center 
interventional study of AMI patients from 19 collaborat-
ing hospitals located in Japan. All patients enrolled in this 
study were randomly allocated to receive 10 mg of either 
atorvastatin or pravastatin once daily and followed up. Evi-
dence-based use of other oral medications for AMI such 
as beta-blockers, anti-platelet agents, and renin–angioten-
sin–aldosterone system inhibitors was left to the treating 
physician’s discretion during the hospitalization period. 
The study protocol was developed in accordance with the 
Declaration of Helsinki and was approved by the ethics 
committee of each participating hospital. All patients gave 
written informed consent before participating in this study.
From the 508 patients registered for the ALPS-AMI 
study, we excluded patients who had Killip class ≥2 and 
individuals who died during hospitalization. We identified 
444 patients who had Killip class 1 on admission and were 
discharged alive. The patients were retrospectively tracked 
for major adverse events from the time of enrollment. The 
primary endpoint of this study was all-cause mortality. 
We compared event rates in the patients who received oral 
beta-blockers (beta group) and those who did not (non-beta 
group).
Definitions and procedures
As previously reported [10], myocardial infarction was 
defined as STEMI or non-ST-segment elevation myocar-
dial infarction. Killip class 1 was defined as no evidence 
of heart failure on admission [11]. All patients were taken 
immediately to the cardiac catheterization laboratory for 
coronary angiography and PCI after receiving 200 mg 
of chewable aspirin and 300 mg of clopidogrel. The pri-
mary PCI was performed within 24 h after the onset of 
AMI, and heparin was given to achieve an activated clot-
ting time between 300 and 350 s. Maintenance doses of 
100 mg of aspirin and 75 mg of clopidogrel were used 
after primary PCI, as reported previously [12]. The final 
coronary blood flow after PCI was assessed accord-
ing to the thrombolysis in myocardial infarction (TIMI) 
classification [13], with procedural success defined as 
TIMI flow grade of 3. Left ventricular ejection fraction 
(LVEF) was measured with echocardiography using 
the biplane Simpson’s method at the time of hospital 
discharge.
Statistical analysis
Continuous variables are presented as mean ± standard 
deviation, whereas dichotomous variables are presented 
as numbers and percentages. Differences between patients 
on beta-blockers and those not on beta-blockers were 
compared using the Chi-squared test for categorical vari-
ables and the unpaired Student’s t test or the Wilcoxon 
rank-sum test, as appropriate, for continuous variables. 
The Kaplan–Meier test was used to analyze the effect of 
beta-blockers on all-cause mortality. The log-rank test 
was used to compare survival curves. Univariate Cox-
proportional hazards analyses were performed to iden-
tify independent predictors of all-cause mortality. Effect 
modification between exposure to beta-blockers and other 
variables was investigated. A propensity score for receiv-
ing beta-blockers was incorporated into the models. The 
propensity score was calculated using a non-parsimoni-
ous multivariate logistic regression model in which the 
outcome variable was use of beta-blockers. From the 
variables that we could collect, we considered follow-
ing as variables to potentially influence the prescription 
of beta-blockers; age, gender, LVEF at discharge, esti-
mated glomerular filtration rate, a history of cerebrovas-
cular disease, prior PCI, use of angiotensin-converting 
enzyme inhibitors or angiotensin receptor blockers, 
B-type natriuretic peptide level, and final TIMI grade ≤2. 
Covariate selection for model entry was based on clinical 
experience and identification of beta-blocker prescription. 
Appropriateness of the model was validated by Hosmer–
Lemeshow goodness-of-fit test. The model which showed 
highest value in the Hosmer–Lemeshow goodness-of-fit 
test was estimated to be appropriate model. We calculated 
propensity score in several models using variables men-
tioned above and found the model including age, LVEF 
at discharge, estimated glomerular filtration rate, use of 
angiotensin-converting enzyme inhibitors or angiotensin 
receptor blockers, B-type natriuretic peptide level, and 
final TIMI grade ≤2, as an appropriate for evaluating the 
efficacy of beta-blockers based on the results of the Hos-
mer–Lemeshow goodness-of-fit test. Propensity score-
adjusted multivariate Cox regression analysis was then 
performed. A p value <0.05 was considered to represent 
statistical significance. Statistical analysis was performed 
using the Statistical Package for Social Sciences, version 
21 (SPSS Inc., Chicago, IL, USA).




The mean duration of follow-up was 1040 ± 186 days. 
The baseline characteristics of the study patients are shown 
in Table 1. Overall, the mean age was 65.2 ± 11.7 years, 
81.8 % of the patients were men, and 81.8 % had STEMI. 
Of the traditional risk factors for atherosclerosis, approxi-
mately one-third of the patients had dyslipidemia, one-
half had hypertension, one-quarter had diabetes mellitus, 
and two-thirds had a history of current or former smoking. 
PCI was successful in 86.9 % of cases. The mean LVEF 
at discharge was 56.0 ± 11.9 %, and 8.1 % of the patients 
had LVEF ≤ 40 %. Among the 444 patients, 251 (56.5 %) 
were prescribed beta-blockers after primary PCI, includ-
ing carvedilol (92.8 %), bisoprolol (4.0 %), and others 
(3.2 %). Except for the history of previous coronary artery 
disease, infarct-related artery, and administration of angio-
tensin-converting enzyme inhibitors or angiotensin recep-
tor blockers, no differences were observed between the 2 
groups.
Incidence of all‑cause mortality
During the follow-up period, the cumulative incidence of 
all-cause mortality was 4.7 % (n = 21) for the entire study 
population, including 7 cases in the beta group and 14 cases 
in the non-beta group. Regarding the primary outcome, 
there were 5 cases of cardiac death due to heart failure and 
Table 1  Baseline characteristics stratified by beta-blocker therapy status
Data are shown as mean ± SD or as n (percentage)
TIMI thrombolysis in myocardial infarction
Variables Beta group (n = 251) Non-beta group (n = 193) p value
Age (years) 65.2 ± 11.7 66.3 ± 11.5 0.327
Body mass index (kg/m2) 23.9 ± 3.2 23.9 ± 3.9 0.944
Female sex 50 (19.9 %) 31 (16.1 %) 0.179
Dyslipidemia 99 (39.4 %) 66 (34.2 %) 0.150
Low-density lipoprotein cholesterol (mg/dl) 133.1 ± 33.7 128.7 ± 34.7 0.198
High-density lipoprotein cholesterol (mg/dl) 47.0 ± 11.4 48.9 ± 12.0 0.115
Diabetes mellitus 61 (24.3 %) 46 (23.8 %) 0.500
Hemoglobin A1C (%) 6.3 ± 1.3 6.3 ± 1.1 0.950
Hypertension 115 (45.8 %) 86 (44.6 %) 0.419
Smoking 168 (66.9 %) 121 (62.7 %) 0.204
Family history of coronary artery disease 60 (23.9 %) 38 (19.7 %) 0.172
Estimated glomerular filtration rate (ml/min) 71.8 ± 19.0 72.3 ± 19.9 0.805
Hemoglobin (g/dl) 14.5 ± 1.8 14.7 ± 2.9 0.437
B-type natriuretic peptide (pg/ml) 71.8 ± 19.0 72.3 ± 19.9 0.805
Left ventricular ejection fraction at discharge 56.0 ± 11.9 56.2 ± 10.6 0.796
Medical history
 Cerebrovascular disease 18 (7.2 %) 9 (4.7 %) 0.186
 Prior percutaneous coronary intervention 16 (6.4 %) 22 (11.4 %) 0.045
 ST-segment elevation myocardial infarction 206 (82.1 %) 157 (81.3 %) 0.363
Infarct-related artery
 Left anterior descending artery 133 (53.0 %) 73 (37.8 %) 0.001
 Left circumflex artery 36 (14.3 %) 31 (16.1 %) 0.355
 Right coronary artery 87 (34.7 %) 89 (46.1 %) 0.009
 Multi-vessel disease 83 (33.1 %) 57 (29.5 %) 0.245
 Final TIMI flow grade ≤2 36 (14.3 %) 22 (11.4 %) 0.221
Medications at discharge
 Statins 251 (100 %) 193 (100 %) 1.000
 Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers 228 (90.8 %) 150 (77.7 %) <0.001
 Calcium channel blockers 40 (15.9 %) 36 (18.7 %) 0.265
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fatal arrhythmia, 9 cases of cerebrovascular death due to 
intracranial hemorrhage and stroke, and 7 cases of non-car-
diovascular death. In the Kaplan–Meier analysis, the inci-
dence of all-cause mortality was significantly lower in the 
beta group compared to the non-beta group (2.7 vs. 7.3 %, 
log-rank p = 0.025) (Fig. 1). The univariate Cox-propor-
tional hazards analysis revealed that age [hazard ratio (HR) 
1.057; 95 % confidence interval (CI) 1.013–1.103], esti-
mated glomerular filtration rate on admission (HR 0.970; 
95 % CI 0.947–0.993), and administration of beta-blockers 
(HR 0.367; 95 % CI 0.148–0.910) were significantly asso-
ciated with lower all-cause mortality (Table 2). To mini-
mize the influence of confounding variables, we also cal-
culated the propensity score for receiving beta-blockers in 
this study population. The Hosmer–Lemeshow goodness-
of-fit test for this model had a p value of 0.961. We then 
performed a multivariate Cox regression analysis with 
adjustment for the calculated propensity score, which also 
showed that beta-blocker therapy was an independent pre-
dictor of all-cause mortality (HR 0.309; 95 % CI 0.116–
0.824; p = 0.019) (Table 2).
Discussion
In the present study, the use of beta-blocker therapy after 
primary PCI was significantly associated with a lower inci-
dence of all-cause mortality in AMI patients with Killip 
class 1. Our results suggest that beta-blocker therapy may 
be beneficial for reducing mortality in relatively low-risk 
AMI patients after primary PCI.
The current guidelines on the use of beta-blocker 
therapy after AMI are based on the data obtained in the 
fibrinolytic era, and the clinical benefit of beta-blocker 
therapy was demonstrated only in patients with left ven-
tricular dysfunction [1]. The guidelines for the manage-
ment of AMI from the American Heart Association/Amer-
ican College of Cardiology and the European Society of 
Cardiology do not mention beta-blocker therapy after pri-
mary PCI. In the current era of primary PCI, it has been 
proposed that beta-blocker therapy might be considered in 
AMI patients according to their individual mortality risks 
[14]. It has also been reported that beta-blocker therapy 
Fig. 1  Kaplan–Meier analysis of all-cause mortality and beta-blocker 
therapy in the overall study population. During a mean follow-up of 
3 years, there was a statistically significant difference in the incidence 
of all-cause mortality between the beta and non-beta groups (2.7 vs. 
7.3 %, log-rank p = 0.025)
Table 2  Cox proportional regression analysis of all-cause mortality
HR hazard ratio, CI confidential interval, TIMI thrombolysis in myocardial infarction
a The potential confounders used in the calculation of the propensity score included age, left ventricular ejection fraction, estimated glomerular 
filtration rate on admission, administration of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, B-type natriuretic pep-
tide level, and final TIMI flow grade ≤2
Variable HR 95 % CI p value
Univariate Cox regression analysis
 Age 1.057 1.013–1.103 0.010
 Female sex 0.463 0.108–1.989 0.301
 Estimated glomerular filtration rate on admission 0.970 0.947–0.993 0.010
 Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers 0.464 0.180–1.197 0.112
 Beta-blockers 0.367 0.148–0.910 0.031
 Left ventricular ejection fraction at discharge 0.987 0.951–1.025 0.497
 B-type natriuretic peptide 1.001 0.999–1.002 0.235
 Final TIMI flow grade ≤ 2 2.176 0.797–5.939 0.129
Multivariate Cox regression analysis adjusted for propensity scorea
 Beta-blockers 0.309 0.116–0.822 0.019
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was associated with reduced mortality in a subgroup of 
patients with low LVEF after primary PCI. Although AMI 
patients with Killip class 1 were shown to have a lower 
mortality than patients with higher Killip classes [8], the 
efficacy of beta-blocker therapy in reducing mortality was 
not fully characterized in such patients. Thus, our find-
ings contribute new insights into the management of AMI 
patients.
The Harmonizing Outcomes with Revascularization and 
Stents in Acute Myocardial Infarction (HORIZONS-AMI) 
trial showed that failure to achieve the TIMI flow grade of 
3 after primary PCI was a powerful predictor of mortality 
[15], and a final TIMI flow grade ≤2 after primary PCI for 
AMI was reported to be associated with poor outcomes 
[16]. In our study, the TIMI flow grade of 3 was achieved in 
86.9 % of the patients, which is consistent with recent Japa-
nese registry data [17]. Primary PCI delays the progression 
of ischemic myocardial injury and salvages the damaged 
but still viable myocardium [18]. Compared to fibrinoly-
sis, primary PCI for AMI has been reported to reduce re-
infarction and mortality, and it may also reduce the degree 
of left ventricular dysfunction after AMI. Although there 
were very few patients with left ventricular dysfunction in 
our study, patients receiving beta-blocker therapy after pri-
mary PCI had a significantly lower incidence of all-cause 
mortality compared to those who did not take beta-block-
ers. A recent study showed that beta-blocker therapy was 
associated with reduced all-cause mortality in AMI patients 
who survived for at least 30 days after discharge [19]. In 
addition to being consistent with this published result, our 
findings demonstrate for the first time that combining statin 
therapy with beta-blocker therapy may reduce the mortality 
in patients with no heart failure on admission.
As mentioned above, beta-blocker therapy after primary 
PCI was efficacious for reducing mortality in high-risk 
patients, but not in AMI patients overall [14, 20]. Bangalore 
et al. [21] reported the use of beta-blockers was not associ-
ated with a lower incidence of composite events in patients 
with prior MI. They also described that the beta-blocker 
use was associated with a lower incidence of cardiovascular 
events only in patients with recent MI (≤1 year). However, 
in the present study, a great reduction in mortality associ-
ated with the use of beta-blocker therapy was observed in 
patients at low risk of cardiovascular events. One differ-
ence between our study and the previous reports [14, 20, 
21] was the proportion of patients on statins in the study 
population. Since in our case the original trial was designed 
for evaluating the efficacy of statins in AMI, all the subjects 
were on statins, compared to approximately 30–50 % of 
the patients in the previous reports. Although study of Ban-
galore et al. [21] was a large number, prospective cohort 
study, the proportion of primary PCI was not mentioned in 
prior MI cohort. Another previous study performed in the 
pre-primary PCI era demonstrated that the combination of 
beta-blockers and statins was associated with a reduction 
of the relative risk of all-cause mortality compared to the 
beta-blocker or statin therapy alone in myocardial infarc-
tion patients with heart failure [22]. This may explain why 
our data showed that beta-blockers were efficacious for 
reducing mortality in AMI patients without heart failure. 
Our findings suggest that the medical treatment after pri-
mary PCI should include beta-blocker therapy for all AMI 
patients, if possible. We propose that the combination of a 
beta-blocker and a statin may substantially reduce mortal-
ity in AMI patients without heart failure.
Study limitations
Our study has several limitations. First, the sample size 
was relatively small. Thus, owing to the limited number of 
events, the study had low statistical power. Second, since 
the ALPS-AMI study was originally designed to assess the 
effect of statins in AMI patients, administration of beta-
blockers after primary PCI was left to the treating physi-
cian’s discretion, which might have resulted in selection 
bias. To address this issue, we calculated the propensity 
score using potential confounders and performed a sup-
plementary Cox regression analysis. Furthermore, no 
data were available on the doses or the way of titration of 
beta-blockers. The data about the onset-to-admission time, 
door-to-balloon time, duration of hospital stay, peak cre-
atinine phosphokinase level after primary PCI, and initial 
TIMI flow grade were not assessed in this study. The day 
of discharge was not also assessed in this study. Therefore, 
the Day 0 was set as the day of admission, which might 
have influenced the results of the Cox-proportional hazard 
models in the present study. Finally, the mean follow-up 
duration was approximately 3 years, and long-term effects 
of beta-blockers after primary PCI should be investigated 
using a larger sample size and a longer follow-up period. 
Despite these limitations, we believe that the use of beta-
blocker therapy after primary PCI might be associated with 
reduced mortality in AMI patients without pump failure in 
the current statin era.
Conclusion
In the statin era, the use of beta-blocker therapy after pri-
mary PCI significantly reduces all-cause mortality com-
pared to the treatment without beta-blocker therapy in 
AMI patients with Killip class 1. A further long-term fol-
low-up study is required to evaluate the long-term effect 
of beta-blocker therapy on cardiovascular events after pri-
mary PCI.
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